BetterLife PharmaBETRF +11.06%26 9-Day RSI is 86.82 as of Jul. 05, 2026. GuruFocus rates BETRF with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,418 Biotechnology companies, BetterLife Pharma ranks worse than 99.29% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
BetterLife Pharma 9-Day RSI Related Terms
BETRF vs VRTX, REGN, ALNY: 9-Day RSI Comparison
For the Biotechnology subindustry, BetterLife Pharma's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BetterLife Pharma 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BetterLife Pharma's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where BetterLife Pharma's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BetterLife Pharma (BETRF) has a 9-Day RSI of 86.82 as of Jul. 05, 2026. According to the industry distribution chart, BetterLife Pharma ranks #1408 out of 1418 companies in the Biotechnology industry, placing it in the top 99.3%.
Is BetterLife Pharma's 9-Day RSI too high?
BetterLife Pharma's current 9-Day RSI is 86.82. The Biotechnology industry median 9-Day RSI is 53.73. BetterLife Pharma's value of 86.82 is 61.6% above this industry median. Based on the distribution chart, BetterLife Pharma ranks #1408 out of 1418 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BetterLife Pharma has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does BetterLife Pharma's 9-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BetterLife Pharma ranks #1408 out of 1418 companies for 9-Day RSI. This places BetterLife Pharma in the lower half of its industry. The industry median 9-Day RSI is 53.73. BetterLife Pharma's value of 86.82 is 61.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 53.73, based on 1,418 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BetterLife Pharma's current 9-Day RSI of 86.82 is 61.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 53.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BetterLife Pharma's current 9-Day RSI is 86.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BetterLife Pharma stock overvalued right now?
BetterLife Pharma (BETRF) has a current 9-Day RSI of 86.82. The current 9-Day RSI is 86.82 and 61.6% above the Biotechnology industry median of 53.73. BetterLife Pharma's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For BetterLife Pharma (BETRF), the current 9-Day RSI is 86.82 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BetterLife Pharma Inc is a biopharmaceutical company engaged in the development of patented pharmaceuticals. It is an emerging biotechnology company mainly focused on developing compounds for the treatment of mental disorders. It is also refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight viral infections. The Company operates in one industry segment, development and commercialization of patented pharmaceuticals within one geographical area.
26GF Score
Get the complete analysis for BETRF
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BETRF has been successfully added to your 